The price of Intellia Therapeutics Inc (NASDAQ:NTLA) shares last traded on Wall Street rose 9.08% to $12.13.
NTLA stock price is now 37.01% away from the 50-day moving average and 3.26% away from the 200-day moving average. The market capitalization of the company currently stands at $1.26B.
With the price target maintained at $21, Wolfe Research recently Upgraded its rating from Peer Perform to Outperform for Intellia Therapeutics Inc (NASDAQ: NTLA). On March 05, 2025, H.C. Wainwright recently initiated its ‘Buy’ rating on the stock quoting a target price of $30, while ‘JP Morgan’ rates the stock as ‘Neutral’
In other news, Clark Eliana, EVP, Chief Technical Officer sold 1,022 shares of the company’s stock on Jul 01 ’25. The stock was sold for $10,036 at an average price of $9.82. Upon completion of the transaction, the EVP, Chief Technical Officer now directly owns 95,369 shares in the company, valued at $1.16 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jul 02 ’25, VP, Chief Accounting Officer Dube Michael P sold 2,503 shares of the business’s stock. A total of $24,905 was realized by selling the stock at an average price of $9.95. This leaves the insider owning 57,137 shares of the company worth $0.69 million. A total of 5.95% of the company’s stock is owned by insiders.
During the past 12 months, Intellia Therapeutics Inc has had a low of $5.90 and a high of $28.18. As of last week, the company has a debt-to-equity ratio of 0.15, a current ratio of 4.90, and a quick ratio of 4.90. The fifty day moving average price for NTLA is $8.8532 and a two-hundred day moving average price translates $11.746825 for the stock.
The latest earnings results from Intellia Therapeutics Inc (NASDAQ: NTLA) was released for 2025-03-31. The net profit margin was -1154.10% and return on equity was -57.92% for NTLA. The company reported revenue of $16.63 million for the quarter, compared to $28.93 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -42.54 percent.
